Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
Executive Summary
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.